Indeterminate human immunodeficiency virus type 1 western blots

Seroconversion risk, specificity of supplemental tests, and an algorithm for evaluation

Connie L. Celum, Robert W. Coombs, William Lafferty, Thomas Inui, Pamela H. Louie, Carol A. Gates, Bruce J. McCreedy, Richard Egan, Thomas Grove, Steve Alexander, Thomas Koepsell, Noel Weiss, Lloyd Fisher, Lawrence Corey, King K. Holmes

Research output: Contribution to journalArticle

52 Citations (Scopus)

Abstract

The human immunodeficiency virus type 1 (HIV-1) Western blot is indeterminate in 10%-20% of sera reactive by EIA. Eighty-nine individuals with prior repeatedly reactive EIA and indeterminate Western blots were followed prospectively to study the risk of seroconversion and specificity of supplemental tests. Four high-risk cases seroconverted within 10 months after enrollment (seroconversion risk, 4.5%, 95% confidence interval, 1.2%-11.1%). Among cases with p24 bands initially, 4 (18.2%) of 22 high-risk individuals seroconverted compared with 0 of 33 low-risk cases (P = .03). Specificities of HIV-1 culture, serum p24 antigen, polymerase chain reaction, and recombinant ENV 9 EIA were 100%, 100%, 98.6%, and 94.4%, respectively. An expedited evaluation protocol is proposed. Low-risk individuals with nonreactive EIAs upon repeat testing do not need further follow-up; high-risk individuals should be followed serologically for at least 6 months, especially those with p24 bands on Western blot.

Original languageEnglish (US)
Pages (from-to)656-664
Number of pages9
JournalJournal of Infectious Diseases
Volume164
Issue number4
StatePublished - Oct 1991
Externally publishedYes

Fingerprint

HIV-1
Western Blotting
Seroconversion
Serum
Confidence Intervals
Antigens
Polymerase Chain Reaction

ASJC Scopus subject areas

  • Public Health, Environmental and Occupational Health
  • Immunology

Cite this

Indeterminate human immunodeficiency virus type 1 western blots : Seroconversion risk, specificity of supplemental tests, and an algorithm for evaluation. / Celum, Connie L.; Coombs, Robert W.; Lafferty, William; Inui, Thomas; Louie, Pamela H.; Gates, Carol A.; McCreedy, Bruce J.; Egan, Richard; Grove, Thomas; Alexander, Steve; Koepsell, Thomas; Weiss, Noel; Fisher, Lloyd; Corey, Lawrence; Holmes, King K.

In: Journal of Infectious Diseases, Vol. 164, No. 4, 10.1991, p. 656-664.

Research output: Contribution to journalArticle

Celum, CL, Coombs, RW, Lafferty, W, Inui, T, Louie, PH, Gates, CA, McCreedy, BJ, Egan, R, Grove, T, Alexander, S, Koepsell, T, Weiss, N, Fisher, L, Corey, L & Holmes, KK 1991, 'Indeterminate human immunodeficiency virus type 1 western blots: Seroconversion risk, specificity of supplemental tests, and an algorithm for evaluation', Journal of Infectious Diseases, vol. 164, no. 4, pp. 656-664.
Celum, Connie L. ; Coombs, Robert W. ; Lafferty, William ; Inui, Thomas ; Louie, Pamela H. ; Gates, Carol A. ; McCreedy, Bruce J. ; Egan, Richard ; Grove, Thomas ; Alexander, Steve ; Koepsell, Thomas ; Weiss, Noel ; Fisher, Lloyd ; Corey, Lawrence ; Holmes, King K. / Indeterminate human immunodeficiency virus type 1 western blots : Seroconversion risk, specificity of supplemental tests, and an algorithm for evaluation. In: Journal of Infectious Diseases. 1991 ; Vol. 164, No. 4. pp. 656-664.
@article{24fb75a2119a40edb8c35937865d911b,
title = "Indeterminate human immunodeficiency virus type 1 western blots: Seroconversion risk, specificity of supplemental tests, and an algorithm for evaluation",
abstract = "The human immunodeficiency virus type 1 (HIV-1) Western blot is indeterminate in 10{\%}-20{\%} of sera reactive by EIA. Eighty-nine individuals with prior repeatedly reactive EIA and indeterminate Western blots were followed prospectively to study the risk of seroconversion and specificity of supplemental tests. Four high-risk cases seroconverted within 10 months after enrollment (seroconversion risk, 4.5{\%}, 95{\%} confidence interval, 1.2{\%}-11.1{\%}). Among cases with p24 bands initially, 4 (18.2{\%}) of 22 high-risk individuals seroconverted compared with 0 of 33 low-risk cases (P = .03). Specificities of HIV-1 culture, serum p24 antigen, polymerase chain reaction, and recombinant ENV 9 EIA were 100{\%}, 100{\%}, 98.6{\%}, and 94.4{\%}, respectively. An expedited evaluation protocol is proposed. Low-risk individuals with nonreactive EIAs upon repeat testing do not need further follow-up; high-risk individuals should be followed serologically for at least 6 months, especially those with p24 bands on Western blot.",
author = "Celum, {Connie L.} and Coombs, {Robert W.} and William Lafferty and Thomas Inui and Louie, {Pamela H.} and Gates, {Carol A.} and McCreedy, {Bruce J.} and Richard Egan and Thomas Grove and Steve Alexander and Thomas Koepsell and Noel Weiss and Lloyd Fisher and Lawrence Corey and Holmes, {King K.}",
year = "1991",
month = "10",
language = "English (US)",
volume = "164",
pages = "656--664",
journal = "Journal of Infectious Diseases",
issn = "0022-1899",
publisher = "Oxford University Press",
number = "4",

}

TY - JOUR

T1 - Indeterminate human immunodeficiency virus type 1 western blots

T2 - Seroconversion risk, specificity of supplemental tests, and an algorithm for evaluation

AU - Celum, Connie L.

AU - Coombs, Robert W.

AU - Lafferty, William

AU - Inui, Thomas

AU - Louie, Pamela H.

AU - Gates, Carol A.

AU - McCreedy, Bruce J.

AU - Egan, Richard

AU - Grove, Thomas

AU - Alexander, Steve

AU - Koepsell, Thomas

AU - Weiss, Noel

AU - Fisher, Lloyd

AU - Corey, Lawrence

AU - Holmes, King K.

PY - 1991/10

Y1 - 1991/10

N2 - The human immunodeficiency virus type 1 (HIV-1) Western blot is indeterminate in 10%-20% of sera reactive by EIA. Eighty-nine individuals with prior repeatedly reactive EIA and indeterminate Western blots were followed prospectively to study the risk of seroconversion and specificity of supplemental tests. Four high-risk cases seroconverted within 10 months after enrollment (seroconversion risk, 4.5%, 95% confidence interval, 1.2%-11.1%). Among cases with p24 bands initially, 4 (18.2%) of 22 high-risk individuals seroconverted compared with 0 of 33 low-risk cases (P = .03). Specificities of HIV-1 culture, serum p24 antigen, polymerase chain reaction, and recombinant ENV 9 EIA were 100%, 100%, 98.6%, and 94.4%, respectively. An expedited evaluation protocol is proposed. Low-risk individuals with nonreactive EIAs upon repeat testing do not need further follow-up; high-risk individuals should be followed serologically for at least 6 months, especially those with p24 bands on Western blot.

AB - The human immunodeficiency virus type 1 (HIV-1) Western blot is indeterminate in 10%-20% of sera reactive by EIA. Eighty-nine individuals with prior repeatedly reactive EIA and indeterminate Western blots were followed prospectively to study the risk of seroconversion and specificity of supplemental tests. Four high-risk cases seroconverted within 10 months after enrollment (seroconversion risk, 4.5%, 95% confidence interval, 1.2%-11.1%). Among cases with p24 bands initially, 4 (18.2%) of 22 high-risk individuals seroconverted compared with 0 of 33 low-risk cases (P = .03). Specificities of HIV-1 culture, serum p24 antigen, polymerase chain reaction, and recombinant ENV 9 EIA were 100%, 100%, 98.6%, and 94.4%, respectively. An expedited evaluation protocol is proposed. Low-risk individuals with nonreactive EIAs upon repeat testing do not need further follow-up; high-risk individuals should be followed serologically for at least 6 months, especially those with p24 bands on Western blot.

UR - http://www.scopus.com/inward/record.url?scp=0025953621&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=0025953621&partnerID=8YFLogxK

M3 - Article

VL - 164

SP - 656

EP - 664

JO - Journal of Infectious Diseases

JF - Journal of Infectious Diseases

SN - 0022-1899

IS - 4

ER -